Anti-CYP26C1 Antibody, clone T6P1C7*E7

32160702

Cytochrome P450 26C1 (UniProt Q6V0L0; also known as CYP26C1, Cytochrome P450, family 26, subfamily C, polypeptide 1) is encoded by the CYP26C1 (also known as FFDD4) gene (Gene ID 340665) in human. Cytochromes P450 (CYP) proteins are primarily membrane-associated oxidases located either in the inner membrane of mitochondria or in the endoplasmic reticulum where they function as the terminal enzymes in electron transfer chains. In addition to processing endogenous substrates, CYPs also function to metabolize exogenous drugs and potentially toxic chemicals. The human CYP superfamily consisits of 57 genes and more than 59 pseudogenes divided into 18 families and 43 subfamilies. The CYP26 subfamily of enzymes (CYP26A1, CYP26B1/CYP26A2, CYP26C1) are retinoic acid hydroxylases responsible for the inactivation of all-trans-retinoic acid (atRA) to hydroxylated forms, such as 4-oxo-, 4-OH-, and 18-OH-atRA, with 4-oxo-RA being the most common metabolite. All-trans-RA represents the most active form of RA and plays a crucial role in the development of multiple organs via its gene regulatory function. 4-oxo-9-cis-retinoic acid (9-cis-RA) and 4-oxo-13-cis-retinoic acid (13-cis-RA) are two atRA stereo-isomers that also play an important role in RA signalling. Immunohistochemistry staining reveals moderate to strong expression of CYP26A1 and CYP26B1 in colon cancer tissues when compared with normal colonic epithelium, while CYP26C1 was not expressed in either type of colon tissue samples. CYP26C1 gene mutations are linked to focal facial dermal dysplasia 4 (FFDD4), a group of developmental defects characterized by bitemporal or preauricular skin lesions resembling aplasia cutis congenita.

Clone T6P1C7*E7 was raised against a CYP26C1 C-terminal sequence 100% conserved among human, mouse, and rat species.

Ovalbumin-conjugated linear peptide corresponging to a C-terminal region sequence of human/mouse/rat CYP26C1.

Immunohistochemistry Analysis: Clone T6P1C7*E7 hybridoma culture supernatant detected cytoplasmic CYP51A1 immunoreactivity in formalin-fixed, paraffin-embedded human liver tissue sections.

ELISA Analysis: Clone T6P1C7*E7 hybridoma culture supernatant deteced ovalbumin-conjugated immunogen peptide by ELISA (Brown, G.T., et al. (2014). PLoS One. 9(3):e90776).

Western Blotting Analysis: Clone T6P1C7*E7 hybridoma culture supernatant deteced the expression of exogenously transfected CYP26C1 in lysates from transfected, but not mock-transfected, human embryonic kidney cells (Brown, G.T., et al. (2014). PLoS One. 9(3):e90776).

Research Category
Signaling
This mouse monoclonal Anti-CYP26C1 Antibody, clone T6P1C7*E7, Cat. No. MABS471 detects levels of CYP26C1, and has been published and validated for use in ELISA, Immunohistochemistry (Paraffin), and Western Blotting.

Evaluated by Western Blotting in human liver microsome lysate.

Western Blotting Analysis: 10 µg/mL of this antibody detected CYP26C1 in 50 µg of human liver microsome lysate.

Protein G purified.
Purified mouse monoclonal IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4) 150 mM NaCl with 0.05% sodium azide.

Format: Purified

Concentration: Please refer to lot specific datasheet.

100

mouse

purified immunoglobulin

primary antibodies

T6P1C7*E7, monoclonal

mouse, human

rat (based on 100% sequence homology)

immunohistochemistry: suitable (paraffin)
western blot: suitable

IgG1κ

NP_899230

Q6V0L0

ambient

~57 kDa observed. 57.11/57.03/57.30 kDa (human/mouse/rat) calculated. Uncharacterized bands may be observed in some lysate(s).

Stable for 1 year at 2-8°C from date of receipt.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

12 - Non Combustible Liquids

WGK 1